Heidelberg Pharma has dosed the first patient with HDP-102, an amanitin-based antibody-drug conjugate targeting CD37, in a Phase I study for relapsed or refractory non-Hodgkin lymphoma.
Heidelberg Pharma's lead ATAC candidate HDP-101 demonstrated safety and tolerability in cohort 7 at 112.50 µg/kg dose for multiple myeloma, with a patient from cohort 5 maintaining complete remission.